Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 27, 2015. The report details a significant clinical milestone for GSK's candidate shingles vaccine, Shingrix, specifically regarding the ZOE-70 Phase III study in adults aged 70 years and over.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial results and regulatory timelines rather than financial performance.
Material Changes and Clinical Results
- Shingles Efficacy: The ZOE-70 study met its primary objective, demonstrating 90% efficacy (95% confidence interval: 84-94) against shingles in adults aged 70 and over compared to placebo.
- PHN Efficacy: A pooled analysis of ZOE-70 and ZOE-50 data showed 89% efficacy in preventing postherpetic neuralgia (PHN) in people aged 70 and over, and 91% efficacy in people aged 50 and over.
- Study Scope: The ZOE-70 trial involved more than 14,800 adults aged 70 and older across North America, Europe, Latin America, and Asia-Pacific.
Guidance, Outlook, and Risks
- Regulatory Timeline: GSK intends to submit regulatory applications for Shingrix in North America, Japan, and the EU during the second half of 2016.
- Safety Profile: The Independent Data Monitoring Committee (IDMC) raised no safety concerns in its review up to April 2015. Common adverse events included local symptoms (pain, redness, swelling) and systemic symptoms (muscle pain, fatigue, headache).
- Forward-Looking Risks: GSK cautions that actual results may differ materially from projections due to risks described in the 2014 Annual Report on Form 20-F. The name "Shingrix" is not yet approved by any regulatory authority.
Investor Verification Checklist
- Verify the final safety data analysis results expected to be disclosed in the coming months.
- Confirm the exact timing of regulatory submissions in H2 2016 for North America, Japan, and the EU.
- Monitor the publication of full study data in peer-reviewed journals and presentation at scientific conferences.
- Review the 2014 Form 20-F for detailed risk factors affecting the commercialization of new vaccines.